This study reports a clinical experience among twenty @entity161 @entity1 treated by @entity1088 during two years and eight months within a range extending from three months to seven years. These twenty @entity1 had previously shown long-term resistance to usual neuroleptics but three out of them met the diagnosis of @entity1032 or @entity74 (F.84.3-ICD 10). These @entity1 were put under @entity1088 for their violent behavior. The methodology was retrospective, descriptive with intra-individual comparison, each @entity1 being his own reference before and after treatment. Diagnosis met @entity2282 criteria and were assessed without using standard examination. This study aimed at assessing once more @entity1088 efficacy and tolerance upon a long time follow up. Single therapy has been the rule and dosages have been progressively increased reaching a mean daily dosage of 350 mg per day. The efficacy, assessed by the way of BPRS, GAF (DSM III-R) and simplified form of CGIS, has been verified in approximately 30% of the @entity1 , mainly concerning positive symptoms. @entity1088 was also able to alleviate severe behavior troubles brought about by delusional states, without this latter being markedly softened when it was a long term one. @entity1088 tolerance has shown it to be satisfactory, however we noticed the occurrence of a @entity1210 with @entity1398 after seventeen weeks of treatment, followed, some days later, by a Quincke @entity4 , which forced to interrupt the treatment. White blood cells came back in a normal range fifteen days later. The other side effects (transitory hypersialorrhea, @entity591 , without clinical and ECG perturbations) have been usually well tolerated and have never caused treatment interruption. No extrapyramidal side effect have been noticed among our twenty @entity1 . The end of this paper consists in the presentation of four clinical cases: one about the efficacy of @entity1088 upon @entity10420 in a @entity74 ; one delusional chronic @entity161 @entity1 whose violence has been controlled despite of the delusion; one paranoid @entity161 @entity1 who has been able to maintain a satisfactory professional and family adaptation; and finally a @entity74 (F.84.3-ICD 10) in whom occurred the only @entity1210 side effect of our study. These four clinical cases have seemed particularly meaningful regarding our clinical experience of @entity1088 which has been lasting for almost seven years now.

[Long-term clinical experience with XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['Clozapine', 'clozapine'] @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental retardation'] @entity10420 :: ('MESH:D000987', 'Disease') :: ['violent antisocial behaviour'] @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema'] @entity2282 :: ('4311', 'Gene') :: ['CD 10'] @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenic'] @entity74 :: ('MESH:D030342', 'Disease') :: ['schizotypital disorder', 'childhood disintegrative disorder'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']
@entity1088 :: (MESH:D003024,Chemical) :: ['clozapine']
